Jemperli Cancer Drug What To Know As GSK Says It Improves Survival For

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=rGvzwT8ZOkQ

Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, the latest findings of a late-stage trial by GSK seeking to expand the use of the treatment. GSK said it would send its trial data to the FDA for regulatory approval.66,200. That’s the average number of endometrial cancer cases diagnosed in the U. S. each year, according to Johns Hopkins Medicine. That represents about 3.4% of all new cancer cases. The average age of women diagnosed with endometrial cancer is 60, while the cancer is more uncommon under age 45, according to the American Cancer Society. Dostarlimab—known generically as Jemperli—was developed by GSK in partnership with the biotech firm AnaptysBio in 2014, as the company expanded into cancer drug sales. The drug was approved by the FDA last year for treating advanced or recurrent cancer with carboplatin and paclitaxel, two drugs used for chemotherapy treatments. GSK has continued to research the possible benefits of using Jemperli as part of its “RUBY” trials, including possible treatment for other types of cancer. What To Know About Adcetris—Pfizer’s Cancer Drug Extended Survival For Patients With Common Lymphoma (Forbes) • • All data is taken from the source: http://forbes.com • Article Link: https://www.forbes.com/sites/tylerrou... • • #enews #newstodayoncnn #newstodayabc #kingworldnews #newstodayinusa #newstodayusa #

#############################

New on site